Concepedia

Robert J. Kreitman

RJ

164

Publications

13.7K

Citations

65

H-Index

1990

Active since

Affiliations

National Cancer Institute(Current)

National Institutes of Health

Center for Cancer Research

The University of Texas MD Anderson Cancer Center

Wake Forest University

Robert J. Kreitman is an author at National Cancer Institute specializing in medicine, immunology, and immunotherapy.

ORCID

Top concepts

Publications per year

1990–2023

164

Publications

164

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600–Mutant Anaplastic Thyroid Cancer

Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg et al. · Journal of Clinical Oncology · 2017 · 848 citations · Full text

, , +15

Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

Robert J. Kreitman, Wyndham H. Wilson, Karen Bergeron et al. · New England Journal of Medicine · 2001 · 508 citations · Full text

Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies

Robert J. Kreitman, Wyndham H. Wilson, Jeffrey D. White et al. · Journal of Clinical Oncology · 2000 · 420 citations

Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

Raffit Hassan, Susie Bullock, Ahalya Premkumar et al. · Clinical Cancer Research · 2007 · 379 citations · Full text

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg et al. · Annals of Oncology · 2022 · 319 citations · Full text

Rows per page

1–5 of 164